Alzamend Neuro Inc stock drops amid sector rotation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 Jan 26
Source: 4
Alzamend Neuro Inc's stock fell by 6.17% as it crossed below its 5-day SMA, indicating a significant downward movement in price.
The decline in Alzamend's stock price occurred amid sector rotation, as broader market indices like the Nasdaq-100 and S&P 500 showed gains of 0.69% and 0.49%, respectively. This suggests that investors may be reallocating their investments away from biotech stocks, impacting Alzamend negatively despite the overall market strength.
This movement raises concerns about investor sentiment towards biotech companies, particularly in light of the recent performance of the broader market. Alzamend may need to address these challenges to regain investor confidence.
Analyst Views on ALZN
Wall Street analysts forecast ALZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALZN is 28.00 USD with a low forecast of 28.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.160
Low
28.00
Averages
28.00
High
28.00
Current: 2.160
Low
28.00
Averages
28.00
High
28.00
About ALZN
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
